Medical devices, healthcare technology and the business of care
PMA approval · P220026

Symplicity Spyral Renal Denervation System

Medtronic, Inc. · Decision date Nov 17, 2023

FDA DECISIONP220026

What did the FDA approve?

FDA records P220026 as an original PMA application. The recorded decision is approval, dated Nov 17, 2023.

FDA approval order statement

The Symplicity Spyral Multi-Electrode Renal Denervation Catheter and the Symplicity G3 RF Generator are indicated to reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Nov 17, 2023

FDA source record

Regulatory record facts

Identifier
P220026
Regulatory pathway
Premarket approval application
Product code
QYI
Decision code
APPR
Decision date
Nov 17, 2023
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Ablation catheter, renal denervation.

Product code
QYI
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P220026 received

    Application receipt date recorded by FDA.

  2. P220026 · FDA decision

    APPR

  3. P220026/S014 · Related supplement

    Symplicity Spyral Renal Denervation System

  4. P220026/S019 · Related supplement

    Symplicity G3 Renal Denervation RF Generator

Timeline entries are records held by MedtechLedger for P220026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220026

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementSep 10, 2026FDA
Medtronic, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3576 Unocal Pl., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records